ViiV Healthcare has renewed its research agreement,
aimed at finding a cure for HIV infection, with the University of North
Carolina – Chapel Hill to the tune of $20M over five years. The parties
have been working together since 2015.
Under the terms of the extended contract, the
companies will continue to collaborate at the HIV Cure Center located on
the university’s campus and will continue their joint ownership of Qura
Therapeutics, created in 2015, to manage the intellectual property,
commercialization, manufacturing and governance needs of the
partnership.
ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK -2.4%), Pfizer (PFE -3.1%) and Shionogi (OTCPK:SGIOY -3.5%).
https://seekingalpha.com/news/3549783-viiv-healthcare-re-ups-unc-chapel-hill
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.